Written by The Sterility Testing Market is witnessing strong growth as manufacturers of sterile pharmaceuticals, biologics, and advanced therapies increase investments in quality assurance. The market is expected to grow from USD 1.88 billion in 2026 to USD 5.15 billion by 2035. Regulatory escalation and the growing complexity of pharmaceutical manufacturing are encouraging organizations to strengthen sterility testing workflows.
The revised EU GMP Annex 1 has increased the focus on contamination control throughout sterile manufacturing processes. At the same time, expanding cell and gene therapy pipelines are creating demand for testing solutions capable of delivering reliable results within shorter production timelines. Contract development and manufacturing organizations are also expanding testing capabilities as pharmaceutical companies increasingly outsource quality-control activities.
Membrane filtration remains the leading test type because of its established role in pharmacopeial protocols, while rapid sterility tests are forecast to grow at a 15.49% CAGR through 2035. The services segment is also projected to expand at an 11.38% CAGR as mid-sized pharmaceutical companies increasingly rely on specialized laboratories. Pharmaceutical and biologics manufacturing continues to represent the largest application area.
North America maintains its leading position, while Europe benefits from strict sterile manufacturing requirements and a strong biologics industry. Asia-Pacific offers significant growth potential due to pharmaceutical manufacturing expansion in China, India, South Korea, and other markets. Emerging opportunities include testing-as-a-service, digital laboratory platforms, automated sterility testing, and real-time release approaches.
Gain valuable insights through comprehensive industry analysis:
Oligonucleotide Synthesis Market Outlook